Search

Your search keyword '"Buonomo, Antonio Riccardo"' showing total 407 results
Start Over Author "Buonomo, Antonio Riccardo"
407 results on '"Buonomo, Antonio Riccardo"'

1. COVID-19 in patients with thymic epithelial tumors with or without Good’s syndrome: a single-center retrospective study

Author

Pietroluongo, Erica, Peddio, Annarita, De Placido, Pietro, Tortora, Marianna, Ottaviano, Margaret, Gelzo, Monica, Cernera, Gustavo, Foggia, Maria, Buonomo, Antonio Riccardo, Pinchera, Biagio, Zappulo, Emanuela, Mercinelli, Simona, Cattaneo, Letizia, Sardanelli, Alessia, Viceconte, Giulio, Scotto, Riccardo, Schiano Moriello, Nicola, Servetto, Alberto, De Angelis, Carmine, Arpino, Grazia, Palmieri, Giovannella, De Placido, Sabino, Bianco, Roberto, Castaldo, Giuseppe, Gentile, Ivan, and Giuliano, Mario

Published
2024
Full Text
View/download PDF

2. Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: A multicenter observational study

Author

Calò, Federica, Onorato, Lorenzo, De Luca, Ilaria, Macera, Margherita, Monari, Caterina, Durante-Mangoni, Emanuele, Massa, Alessia, Gentile, Ivan, Di Caprio, Giovanni, Pagliano, Pasquale, Numis, Fabio Giuliano, Iuliano, Pasquale, Buonomo, Antonio Riccardo, Leone, Sebastiano, Maggi, Paolo, and Coppola, Nicola

Published
2023
Full Text
View/download PDF

3. CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE – a multi-centre experience in Italy

Author

Gentile, Ivan, Buonomo, Antonio Riccardo, Corcione, Silvia, Paradiso, Laurenza, Giacobbe, Daniele Roberto, Bavaro, Davide Fiore, Tiseo, Giusy, Sordella, Francesca, Bartoletti, Michele, Palmiero, Giulia, Vozza, Antonietta, Vena, Antonio, Canta, Francesca, Moriello, Nicola Schiano, Congera, Paola, Karruli, Arta, Tascini, Carlo, Viale, Pierluigi, Bono, Valerio Del, Falcone, Marco, Carbonara, Sergio, Mikulska, Malgorzata Karolina, Bassetti, Matteo, Durante-Mangoni, Emanuele, De Rosa, Francesco Giuseppe, and Maraolo, Alberto Enrico

Published
2023
Full Text
View/download PDF

4. Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study

Author

Buonomo, Antonio Riccardo, Viceconte, Giulio, Calabrese, Massimiliano, De Luca, Giovanna, Tomassini, Valentina, Cavalla, Paola, Maniscalco, Giorgia Teresa, Ferraro, Diana, Nociti, Viviana, Radaelli, Marta, Buscarinu, Maria Chiara, Paolicelli, Damiano, Gajofatto, Alberto, Annovazzi, Pietro, Pinardi, Federica, Di Filippo, Massimiliano, Cordioli, Cinzia, Zappulo, Emanuela, Scotto, Riccardo, Gentile, Ivan, Spiezia, Antonio Luca, Petruzzo, Martina, De Angelis, Marcello, Brescia Morra, Vincenzo, Solaro, Claudio, Gasperini, Claudio, Cocco, Eleonora, Moccia, Marcello, and Lanzillo, Roberta

Published
2022
Full Text
View/download PDF

6. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

Author

Mazzaro, Cesare, Bertola, Manuela, Schioppa, Ornella, Benedetti, Antonio, Schiadà, Laura, Cucco, Monica, Giacometti, Andrea, Brescini, Laura, Castelletti, Sefora, Fiorentini, Alessandro, Angarano, Gioacchino, Milella, Michele, Di Leo, Alfredo, Rendina, Maria, D'abramo, Fulvio Salvatore, Lillo, Chiara, Iannone, Andrea, Piazzolla, Mariano, Verucchi, Gabriella, Badia, Lorenzo, Piscaglia, Fabio, Benevento, Francesca, Serio, Ilaria, Castelli, Francesco, Zaltron, Serena, Spinetti, Angiola, Odolini, Silvia, Bruno, Raffaele, Mondelli, Mario, Chessa, Luchino, Loi, Martina, Torti, Carlo, Costa, Chiara, Mazzitelli, Maria, Pisani, Vincenzo, Scaglione, Vincenzo, Trecarichi, Enrico Maria, Zignego, Anna Linda, Monti, Monica, Madia, Francesco, Blanc, Pier Luigi, Attala, Letizia, Pierotti, Piera, Salomoni, Elena, Mariabelli, Elisa, Santantonio, Teresa Antonia, Bruno, Serena Rita, Cela, Ester Marina, Bassetti, Matteo, Mazzarello, Giovanni, Alessandrini, Anna Ida, Di Biagio, Antonio, Nicolini, Laura Ambra, Raimondo, Giovanni, Filomia, Roberto, Aghemo, Alessio, Meli, Rossella, Lazzarin, Adriano, Morsica, Giulia, Salpietro, Stefania, Galli, Massimo, Fracanzani, Anna Ludovica, Fatta, Erika, Lombardi, Rosa, Lampertico, Pietro, Borghi, Marta, D'ambrosio, Roberta, Degasperi, Elisabetta, Puoti, Massimo, Baiguera, Chiara, D'amico, Federico, Vinci, Maria, Rumi, Maria Grazia, Zuin, Massimo, Giorgini, Alessia, Zermiani, Paola, Andreone, Pietro, Caraceni, Paolo, Margotti, Marzia, Guarneri, Valeria, Villa, Erica, Bernabucci, Veronica, Bristot, Laura, Paradiso, Maria Luisa, Migliorino, Guglielmo, Beretta, Ilaria, Gambaro, Alessandra, Lapadula, Giuseppe, Spolti, Anna, Soria, Alessandro, Invernizzi, Pietro, Ciaccio, Antonio, LucÀ, Martina, Malinverno, Federica, Ratti, Laura, Coppola, Carmine, Amoruso, Daniela Caterina, Pisano, Federica, Scarano, Ferdinando, Staiano, Laura, Morisco, Filomena, Cossiga, Valentina, Gentile, Ivan, Buonomo, Antonio Riccardo, Foggia, Maria, Zappulo, Emanuela, Federico, Alessandro, Dallio, Marcello, Coppola, Nicola, Sagnelli, Caterina, Martini, Salvatore, Monari, Caterina, Nardone, Gerardo, Sgamato, Costantino, Chemello, Liliana, Cavalletto, Luisa, Sterrantino, Daniela, Russo, Francesco Paolo, Zanetto, Alberto, Zanaga, Paola, Barbaro, Francesco, Brancaccio, Giuseppina, Craxì, Antonio, Petta, Salvatore, Calvaruso, Vincenza, Crapanzano, Luciano, Madonia, Salvatore, Cannizzaro, Marco, Bruno, Erica Maria, Licata, Anna, Amodeo, Simona, Capitano, Adele Rosaria, Ferrari, Carlo, Laccabue, Diletta, Negri, Elisa, Orlandini, Alessandra, Pesci, Marco, Gulminetti, Roberto, Pagnucco, Layla, Parruti, Giustino, Di Stefano, Paola, Brunetto, Maurizia Rossana, Coco, Barbara, Massari, Marco, Corsini, Romina, Garlassi, Elisa, Andreoni, Massimo, Teti, Elisabetta, Cerva, Carlotta, Baiocchi, Lorenzo, Tata, Xhimi, Grassi, Giuseppe, Gasbarrini, Antonio, Pompili, Maurizio, De Siena, Martina, Taliani, Gloria, Biliotti, Elisa, Spaziante, Martina, Persico, Marcello, Masarone, Mario, Aglitti, Andrea, Calvanese, Gemma, Anselmo, Marco, De Leo, Pasqualina, Marturano, Monica, Saracco, Giorgio Maria, Ciancio, Alessia, Ieluzzi, Donatella, Quaranta, Maria Giovanna, Ferrigno, Luigina, D'Angelo, Franca, Saracino, Annalisa, and Kondili, Loeta A.

Published
2021
Full Text
View/download PDF

8. Epilobium angustifolium L. extract with high content in oenothein B on benign prostatic hyperplasia: A monocentric, randomized, double-blind, placebo-controlled clinical trial

Author

Esposito, Cristina, Santarcangelo, Cristina, Masselli, Raffaello, Buonomo, Giuseppe, Nicotra, Giovanna, Insolia, Violetta, D'Avino, Maria, Caruso, Giuseppe, Buonomo, Antonio Riccardo, Sacchi, Roberto, Sommella, Eduardo, Campiglia, Pietro, Tenore, Gian Carlo, and Daglia, Maria

Published
2021
Full Text
View/download PDF

9. SARS-CoV-2 in Kidney Transplant Patients: A Real-Life Experience

Author

Biagio Pinchera, Lorenzo Spirito, Lucia Ferreri, Roberto La Rocca, Giuseppe Celentano, Antonio Riccardo Buonomo, Maria Foggia, Riccardo Scotto, Stefano Federico, Ivan Gentile, Rosa Carrano, “Federico II” COVID-19 Team, Amicone Maria, Borrelli Francesco, Buonomo Antonio Riccardo, Cattaneo Letizia, Conte Maria Carmela Domenica, Cotugno Mariarosaria, Di Filippo Giovanni, Foggia Maria, Gallicchio Antonella, Gentile Ivan, Giaccone Agnese, Lanzardo Amedeo, Mercinelli Simona, Minervini Fulvio, Piccione Amerigo, Pinchera Biagio, Reynaud Laura, Salemi Fabrizio, Sardanelli Alessia, Schiano Moriello Nicola, Scordino Fabrizio, Scotto Riccardo, Stagnaro Francesca, Tosone Grazia, Viceconte Giulio, Zappulo Emanuela, and Zotta Irene

Subjects
kidney transplant, SARS-CoV-2, COVID-19, transplant, immunosuppression, Medicine (General), R5-920
Abstract

BackgroundThe COVID-19 pandemic has significantly impacted the management of solid organ transplant recipients and on clinical evolution in post-transplantation. Little is known on the impact of SARS-CoV-2 infection in these patients. The severity and lethality of this disease in solid organ transplant patients are higher thanin the general population. This study aims to describe clinical characteristics of SARS-CoV-2 infection in solid organ transplant recipients followed in our center.MethodsIn this observational study, we enrolled all kidney transplant recipientsattending the A.O.U. Federico II of Naples from March 2020 to January 2021. For each patient we evaluated the epidemiological and clinical characteristics as well as outcome.ResultsWe enrolled 369 kidney transplant patients (229, male, 62%). Of these, 51 (13.8%) acquired SARS-CoV-2 infection and 29 showed symptomatic disease. Of the 51 patients with the infection, 48 (94.11%) had at least one comorbidity and such comorbidities did not constitute a risk factor for a more severe disease. Hospitalization was necessary for 7 (13.7%) patients. Of these, 2 required low-flow oxygen supplementation, 3 non-invasive/high flow ventilation and 2 invasive ventilation. Finally, 2 patients died.ConclusionsOur study shows a lower mortality and hospitalization rate compared to figures available in the literature (4% vs. 13–30% and 14% vs. 32–100%, respectively). Furthermore, the comorbidities examined (hypertension, dyslipidemia, and diabetes) did not constitute a risk factor for a more severe disease condition in this patient category. Further studies with larger sample size are necessary to confirm these data.

Published
2022
Full Text
View/download PDF

10. Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: the DALBADIA retrospective cohort study.

Author

Ruiz, Laura Morata, primary, Ruggieri, Alessandro, additional, Falcone, Marco, additional, Liaño, Juan Pasquau, additional, Gentile, Ivan, additional, Lletí, Miguel Salavert, additional, Núñez, Leonor Moreno, additional, Cascio, Antonio, additional, Tascini, Carlo, additional, Yagüe, Maria Bélen Loeches, additional, De Rosa, Francesco Giuseppe, additional, Ori, Alessandra, additional, Comandini, Alessandro, additional, Cattaneo, Agnese, additional, Grossi, Paolo Antonio, additional, Martínez, Antonio Moreno, additional, Vidal, Montserrat Solà, additional, Hidalgo, Carmen, additional, Garcia, Carol, additional, Sequera, Sergio, additional, Tiseo, Giusy, additional, Barbieri, Chiara, additional, Sponga, Pietro, additional, Urso, Donato, additional, Pinchera, Biagio, additional, Buonomo, Antonio Riccardo, additional, Scirocco, Maria Michela, additional, Cotrufo, Marco, additional, Fortes, Agnese Zanus, additional, Rovelli, Cristina, additional, Peghin, Maddalena, additional, Graziano, Elena, additional, Nieto, Alicia Rico, additional, Loidi, Julen Cadiñanos, additional, Anastasia, Antonio, additional, Mancuso, Alessandro, additional, Bonura, Silvia, additional, Lupia, Tommaso, additional, Degioanni, Maria, additional, Tovar, Sandra Cuéllar, additional, and Segarra, Inmaculada, additional

Published
2024
Full Text
View/download PDF

11. Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study

Author

Buonomo, Antonio Riccardo, Viceconte, Giulio, Calabrese, Massimiliano, De Luca, Giovanna, Tomassini, Valentina, Cavalla, Paola, Maniscalco, Giorgia Teresa, Ferraro, Diana, Nociti, Viviana, Radaelli, Marta, Buscarinu, Maria Chiara, Paolicelli, Damiano, Gajofatto, Alberto, Annovazzi, Pietro, Pinardi, Federica, Di Filippo, Massimiliano, Cordioli, Cinzia, Zappulo, Emanuela, Scotto, Riccardo, Gentile, Ivan, Spiezia, Antonio Luca, Petruzzo, Martina, De Angelis, Marcello, Morra, Vincenzo Brescia, Solaro, Claudio, Gasperini, Claudio, Cocco, Eleonora, Moccia, Marcello, and Lanzillo, Roberta

Published
2022
Full Text
View/download PDF

14. Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program.

Author

Viceconte, Giulio, Buonomo, Antonio Riccardo, Esposito, Nunzia, Cattaneo, Letizia, Somma, Teresa, Scirocco, Maria Michela, Mainolfi, Ciro Gabriele, and Gentile, Ivan

Subjects
SPONDYLODISCITIS, SALVAGE therapy, CANDIDA, SHORT bowel syndrome, TREATMENT duration
Abstract

Candida spp. spondylodiscitis is a rare condition for which treatment options are often limited. A further obstacle is the duration of therapy, which should be administered for up to twelve months. In view of the long duration of therapy, azoles are, so far, the only oral treatment strategy that can be given as home therapy. In the case of resistance or reduced susceptibility to azoles, there are not enough comfortable treatment opportunities with adequate bone penetration and limited toxicity. We report the first case of the successful use of rezafungin for spondylodiscitis due to Candida parapsilosis with reduced susceptibility to azoles. A 68-year-old patient, affected by paraplegia and short bowel syndrome, was diagnosed with Candida parapsilosis spondylodiscitis, confirmed with a culture on vertebral biopsy after an 18-FDG PET/CT scan. He received 200 mg of rezafungin weekly for 26 weeks, after 10 weeks of previous antifungal treatment that was not well tolerated with voriconazole plus liposomal amphotericin B. He had a full clinical, radiologic, and biochemical response to the therapy with rezafungin, with no adverse effects. Rezafungin can be a promising therapy for Candida osteomyelitis, especially when first line therapies are ineffective, poorly tolerated, or contraindicated. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort)

Author

Gentile, Ivan, Scotto, Riccardo, Coppola, Carmine, Staiano, Laura, Amoruso, Daniela Caterina, De Simone, Teresa, Portunato, Federica, De Pascalis, Stefania, Martini, Salvatore, Macera, Margherita, Viceconte, Giulio, Tosone, Grazia, Buonomo, Antonio Riccardo, Borgia, Guglielmo, and Coppola, Nicola

Published
2019
Full Text
View/download PDF

19. Risk Factors for Pneumocystis jirovecii Pneumonia in Non-HIV Patients Hospitalized for COVID-19: A Case-Control Study

Author

Viceconte, Giulio, primary, Buonomo, Antonio Riccardo, additional, D'Agostino, Alessia, additional, Foggia, Maria, additional, Di Fusco, Antonio, additional, Pinchera, Biagio, additional, Scotto, Riccardo, additional, Iacovazzo, Carmine, additional, Fanasca, Luca, additional, Messina, Gaetana, additional, Cacciatore, Francesco, additional, Salvatore, Paola, additional, and Gentile, Ivan, additional

Published
2023
Full Text
View/download PDF

21. Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort)

Author

Buonomo, Antonio Riccardo, Scotto, Riccardo, Coppola, Carmine, Pinchera, Biagio, Viceconte, Giulio, Rapillo, Costanza Maria, Staiano, Laura, Saturnino, Mariarosaria, Scarano, Ferdinando, Portunato, Federica, Pisaturo, Mariantonietta, De Pascalis, Stefania, Martini, Salvatore, Tosone, Grazia, Nappa, Salvatore, Coppola, Nicola, and Gentile, Ivan

Published
2020
Full Text
View/download PDF

23. COVID-19 in solid organ transplant recipients after 2 years of pandemic: Outcome and impact of antiviral treatments in a single-center study

Author

Pinchera, Biagio, primary, Buonomo, Antonio Riccardo, additional, Trucillo, Emilia, additional, Susini, Stefano, additional, D’Agostino, Alessia, additional, Di Filippo, Isabella, additional, Tanzillo, Anastasia, additional, Villari, Riccardo, additional, Carrano, Rosa, additional, Troisi, Roberto Ivan, additional, and Gentile, Ivan, additional

Published
2023
Full Text
View/download PDF

24. Outcome of patients with Carbapenem-Resistant Acinetobacter baumannii infections treated with cefiderocol: a multicenter observational study

Author

Calò, Federica, primary, Onorato, Lorenzo, additional, De Luca, Ilaria, additional, Macera, Margherita, additional, Monari, Caterina, additional, Durante-Mangoni, Emanuele, additional, Massa, Alessia, additional, Gentile, Ivan, additional, Caprio, Giovanni Di, additional, Pagliano, Pasquale, additional, Numis, Fabio Giuliano, additional, Iuliano, Pasquale, additional, Buonomo, Antonio Riccardo, additional, Leone, Sebastiano, additional, Maggi, Paolo, additional, and Coppola, Nicola, additional

Published
2023
Full Text
View/download PDF

25. Multidisciplinary approach for rare thoracic tumors during COVID-19 pandemic

Author

Pietroluongo, Erica, primary, De Placido, Pietro, additional, Picozzi, Fernanda, additional, Morra, Rocco, additional, Tortora, Marianna, additional, Del Deo, Vitantonio, additional, Montella, Liliana, additional, Palmieri, Giovannella, additional, Buonomo, Antonio Riccardo, additional, De Placido, Sabino, additional, Gentile, Ivan, additional, and Giuliano, Mario, additional

Published
2023
Full Text
View/download PDF

26. Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection

Author

Pinchera,Biagio, Zappulo,Emanuela, Buonomo,Antonio Riccardo, Cotugno,Maria Rosaria, Di Filippo,Giovanni, Borrelli,Francesco, Mercinelli,Simona, Villari,Riccardo, Gentile,Ivan, Pinchera,Biagio, Zappulo,Emanuela, Buonomo,Antonio Riccardo, Cotugno,Maria Rosaria, Di Filippo,Giovanni, Borrelli,Francesco, Mercinelli,Simona, Villari,Riccardo, and Gentile,Ivan

Abstract

Biagio Pinchera, Emanuela Zappulo, Antonio Riccardo Buonomo, Maria Rosaria Cotugno, Giovanni Di Filippo, Francesco Borrelli, Simona Mercinelli, Riccardo Villari, Ivan Gentile Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples “Federico II”, Naples, ItalyCorrespondence: Biagio Pinchera, Email biapin89@virgilio.itBackground: HCV-related liver disease is an important cause of morbidity and mortality in patients with HIV infection. It is well known that the response rates to HCV therapy are similar between HCV-monoinfected patients and HIV-HV coinfected ones. The aim of this study was to evaluate the impact of HCV eradication on CD4 + T cell count in a population of HIV-HCV coinfected patients.Materials and Methods: We enrolled patients with HIV-HCV coinfection attending the Infectious Diseases Unit of the A.O.U. Federico II of Naples, from January 2016 to February 2019, treated with ART (AntiRetroviral Therapy) and DAAs (Direct Antiviral Agents). For each patient, we evaluated HIV and HCV viral load and CD4+ T cell count before starting therapy with DAAs, by SVR12 time and by SVR48 time. Fibrosis was evaluated by the mean of Fibroscan®.Results: Fifty-two patients were enrolled, 40 males. Fibrosis score was F0-F3 in 15 patients and cirrhosis in the remaining 11 (all in Child-Pugh class A). All had been receiving ART, and all were treated with DAAs. Only patient who had not achieved HIV viral suppression for non-compliance also experienced a relapse of HCV infection after the end of DAAs. In all patients, we observed that the CD4+ T cell count at baseline did not show significant variations compared to SVR12 and SVR48 time. We also assessed CD4 count in relation to HIV categories and stage of liver disease, see Table 1. Also, based on the assessments of the subclasses considered, there were no significant changes in the CD4 + T cell count.Conclusion: Our study shows that HCV viral eradication obtained with DAAs in patie

Published
2023

27. Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study

Author

Gentile, Ivan, Scotto, Riccardo, Schiano Moriello, Nicola, Pinchera, Biagio, Villari, Riccardo, Trucillo, Emilia, Ametrano, Luigi, Fusco, Ludovica, Castaldo, Giuseppe, Buonomo, Antonio Riccardo, Federico Ii Covid Team, null, Gentile, Ivan, Scotto, Riccardo, Schiano Moriello, Nicola, Pinchera, Biagio, Villari, Riccardo, Trucillo, Emilia, Ametrano, Luigi, Fusco, Ludovica, Castaldo, Giuseppe, Buonomo, Antonio Riccardo, and Federico Ii Covid Team, Null

Subjects
Pharmacology, Infectious Diseases, SARS-CoV-2, adverse drug reaction, Drug Discovery, Immunology, COVID-19, molnupiravir, Pharmacology (medical), nirmatrelvir/ritonavir, hospitalization, adverse drug reactions
Abstract

Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and infected with variants different from those currently circulating. We conducted a retrospective study on patients with confirmed SARS-CoV-2 infection treated with OAs during the omicron surge in Italy in order to provide real-life data on the efficacy and safety of OAs during the omicron surge of the COVID-19 pandemic. Among 257 patients, 56.8% received molnupiravir, while 43.2% received nirmatrelvir/ritonavir. Patients in the molnupiravir group were older, had a lower body mass index, and had a higher rate of chronic heart disease than those treated with nirmatrelvir/ritonavir. Three hospitalizations were recorded in the molnupiravir (2.1%) group and one in the nirmatrelvir/ritonavir (0.9%) group. One patient treated with molnupiravir died. The median time to negativity was 8 days in the nirmatrelvir/ritonavir group vs. 10 days in the molnupiravir group, p < 0.01. We recorded 37 ADRs (mainly dysgeusia, diarrhea, and nausea) in 31 individuals (12.1%). Only two patients (0.8%) treated with molnupiravir terminated treatment due to ADRs. In conclusion, in a population of mostly vaccinated patients treated with OAs, we observed a low rate of hospitalization, death, and adverse drug reactions. These rates were lower than those reported in pivotal trials.

Published
2022
Full Text
View/download PDF

28. Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience

Author

Moriello, Nicola Schiano, primary, Buonomo, Antonio Riccardo, additional, Scotto, Riccardo, additional, Pinchera, Biagio, additional, Sarno, Marina, additional, Fusco, Ludovica, additional, Viceconte, Giulio, additional, Iuliano, Antonio, additional, Zappulo, Emanuela, additional, Foggia, Maria, additional, Villari, Riccardo, additional, and Gentile, Ivan, additional

Published
2023
Full Text
View/download PDF

31. Impact of oral antiviral therapy against HCV on gut microbiota. A prospective study

Author

Biagio Pinchera, Scotto Riccardo, Zappulo Emanuela, Buonomo Antonio Riccardo, Maraolo Alberto Enrico, Schiano Moriello Nicola, Viceconte Giulio, Cattaneo Letizia, Villari Riccardo, Gison Flavia, De Filippis Francesca, Ercolini Danilo, and Gentile Ivan

Abstract

The intestinal microbiota plays a fundamental role in physiological homeostasis as well as in pathologic conditions. Hepatitis C virus is the leading cause of chronic liver diseases wordwide. The treatment of this infection has been revolutioned by the availability of direct-acting antiviral agent which guarantee high rate (about 95%) of viral clearance. Few studies have assessed the change in gut microbiota in patients treated with direct-acting antiviral agents against HCV and many aspects still need to be clarified. The aim of the study was to evaluate the effects of antiviral therapy on gut microbiota. We enrolled patients with HCV-related chronic liver disease attending the Infectious Diseases Unit of the A.O.U. Federico II of Naples, from January 2017 to March 2018, treated with DAAs. For each patient, a fecal sample was collected and analyzed for the assessment of the microbial diversity before the start of therapy and by SVR12 time. We exluded patients who received antibiotics in the last 6 months. Twelve patients were enrolled (6 male, 8 genotype 1 (1 subtype 1a), 4 genotype 2). Fibrosis score were F0 in 1 patient, F2 in 1 patient, F3 in 4 patients and cirrhosis in the remaining 6 (all in Child-Pugh class A). All were treated with DAAs for 12 weeks (5 with Paritaprevir-Ombitasvir-Ritonavir-Dasabuvir, 3 with Sofosbuvir-Ledipasvir, 1 with Sofosbuvir-Ribavirin, 1 with Sofosbuvir-Daclatasvir, 1 with Sofosbuvir-Velpatasvir) and 100% achieved SVR12. In all patients, we observed a trend in reduction of potentially pathogenic microorganisms (i.e. Enterobacteriaceae). Furthermore, a trend of increase in α-diversity was observed in patients by SVR12 compared to baseline. This trend was markedly more evident in patients without liver cirrhosis than in those with cirrhosis. Our study shows that viral eradication obtained with DAA is associated with a trend in restoring the heterogeneity of α-diversity and in reducing the percentage of potentially pathogenic microbial species, although this benefit is less evident in patients with cirrhosis. Further studies with larger sample size are necessary to confirm these data.

Published
2022

33. Trends in Caesarean Section Rate According to Robson Group Classification among Pregnant Women with SARS-CoV-2 Infection: A Single-Center Large Cohort Study in Italy

Author

Sirico, Angelo, primary, Carbone, Luigi, additional, Avino, Luisa, additional, Buonfantino, Cira, additional, De Angelis, Maria Chiara, additional, Cresce, Marco Di, additional, Fabozzi, Annamaria, additional, Improda, Francesco Paolo, additional, Legnante, Antonietta, additional, Riccardi, Carla, additional, Santoro, Romina, additional, Vallone, Roberta, additional, Zizolfi, Brunella, additional, Buonomo, Antonio Riccardo, additional, Gentile, Ivan, additional, Salomè, Serena, additional, Raimondi, Francesco, additional, Bifulco, Giuseppe, additional, and Guida, Maurizio, additional

Published
2022
Full Text
View/download PDF

34. Effectiveness and Tolerability of Early Treatment with Monoclonal Antibodies against SARS-Cov-2: Results from A Real-Life Study before Omicron Surge

Author

Scotto, Riccardo, primary, Buonomo, Antonio Riccardo, additional, Zumbo, Giulia, additional, Di Fusco, Antonio, additional, Esposito, Nunzia, additional, Di Filippo, Isabella, additional, Nobile, Mariano, additional, Pinchera, Biagio, additional, Schiano Moriello, Nicola, additional, Villari, Riccardo, additional, and Gentile, Ivan, additional

Published
2022
Full Text
View/download PDF

37. Should SARS CoV-2 infection be considered an independent risk factor for Pneumocystis jirovecii pneumonia? Emerging data after two years of pandemic from a single center experience

Author

Buonomo, Antonio Riccardo, Viceconte, Giulio, Pinchera, Biagio, Scotto, Riccardo, Zappulo, Emanuela, Foggia, Maria, Gentile, Ivan, Buonomo, Antonio Riccardo, Viceconte, Giulio, Pinchera, Biagio, Scotto, Riccardo, Zappulo, Emanuela, Foggia, Maria, and Gentile, Ivan

Subjects
Pharmacology, General Medicine
Published
2022

38. A Simple Non-Invasive Score Based on Baseline Parameters Can Predict Outcome in Patients with COVID-19

Author

Scotto, Riccardo, Lanzardo, Amedeo, Buonomo, Antonio Riccardo, Pinchera, Biagio, Cattaneo, Letizia, Sardanelli, Alessia, Mercinelli, Simona, Viceconte, Giulio, Perrella, Alessandro, Esposito, Vincenzo, Codella, Alessio Vinicio, Maggi, Paolo, Zappulo, Emanuela, Villari, Riccardo, Foggia, Maria, Gentile, Ivan, Federico Ii Covid-Team, null, Scotto, Riccardo, Lanzardo, Amedeo, Buonomo, Antonio Riccardo, Pinchera, Biagio, Cattaneo, Letizia, Sardanelli, Alessia, Mercinelli, Simona, Viceconte, Giulio, Perrella, Alessandro, Esposito, Vincenzo, Codella, Alessio Vinicio, Maggi, Paolo, Zappulo, Emanuela, Villari, Riccardo, Foggia, Maria, Gentile, Ivan, and Federico Ii Covid-Team, Null

Subjects
Pharmacology, COVID-19, SARS-CoV-2, C-reactive protein, P/F ratio, LDH, mortality, Infectious Diseases, Drug Discovery, Immunology, Pharmacology (medical)
Abstract

We evaluated the role of CRP and other laboratory parameters in predicting the worsening of clinical conditions during hospitalization, ICU admission, and fatal outcome among patients with COVID-19. Consecutive adult inpatients with SARS-CoV-2 infection and respiratory symptoms treated in three different COVID centres were enrolled, and they were tested for laboratory parameters within 48 h from admission. Three-hundred ninety patients were enrolled. Age, baseline CRP, and LDH were associated with a P/F ratio < 200 during hospitalization. Male gender and CRP > 60 mg/L were shown to be independently associated with ICU admission. Lymphocytes < 1000 cell/μL were associated with the worst P/F ratio. CRP > 60 mg/L predicted exitus. We subsequently devised an 11-points numeric ordinary scoring system based on age, sex, CRP, and LDH at admission (ASCL score). Patients with an ASCL score of 0 or 2 were shown to be protected against a P/F ratio < 200, while patients with an ASCL score of 6 to 8 were shown to be at risk for P/F ratio < 200. Patients with an ASCL score ≥ 7 had a significantly increased probability of death during hospitalization. In conclusion, patients with elevated CRP and LDH and an ASCL score > 6 at admission should be prioritized for careful respiratory function monitoring and early treatment to prevent a progression of the disease.

Published
2022

39. Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge

Author

Scotto, Riccardo, Buonomo, Antonio Riccardo, Zumbo, Giulia, Di Fusco, Antonio, Esposito, Nunzia, Di Filippo, Isabella, Nobile, Mariano, Pinchera, Biagio, Schiano Moriello, Nicola, Villari, Riccardo, Gentile, Ivan, Federico Ii Covid Team, null, Scotto, Riccardo, Buonomo, Antonio Riccardo, Zumbo, Giulia, Di Fusco, Antonio, Esposito, Nunzia, Di Filippo, Isabella, Nobile, Mariano, Pinchera, Biagio, Schiano Moriello, Nicola, Villari, Riccardo, Gentile, Ivan, and Federico Ii Covid Team, Null

Subjects
Pharmacology, Infectious Diseases, SARS-CoV-2, Drug Discovery, Immunology, early treatment, COVID-19, serology, Pharmacology (medical), real-life, immunodeficiency, monoclonal antibodie, chronic kidney disease
Abstract

Despite the lightning-fast advances in the management of SARS-CoV after 2 years of pandemic, COVID-19 continues to pose a challenge for fragile patients, who could benefit from early administration of monoclonal antibodies (mAbs) to reduce the risk of severe disease progression. We conducted a prospective study to evaluate the effectiveness of mAbs against SARS-CoV-2 among patients at risk for severe disease progression, namely elderly and those with comorbidities, before the omicron variant surge. Patients were treated with either casirivimab/imdevimab, sotrovimab, or bamlanivimab/etesevimab. The rates and risk factors for clinical worsening, hospitalization, ICU admission and death (unfavorable outcomes) were evaluated. A stratified analysis according to the presence of SARS-CoV-2 IgG was also performed. Among 185 included patients, we showed low rates of unfavorable outcomes (9.2%), which were more frequent in patients with chronic kidney disease (aOR: 10.44, 95% CI: 1.73–63.03; p < 0.05) and basal D-dimer serum concentrations > 600 ng/mL (aOR 21.74, 95% CI: 1.18–397.70; p < 0.05). Patients with negative SARS-CoV-2 serology at baseline showed higher C-reactive protein values compared with patients with positive serology (p < 0.05) and a trend toward a higher admission rate to SICU and ICU compared with patients with positive serology. Our results thus showed, in a real-life setting, the efficacy of mAbs against SARS-CoV-2 before an Omicron surge when the available mabs become not effective.

Published
2022

40. Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019 (COVID-19)

Author

Buonomo, Antonio Riccardo, Saccone, Gabriele, Esposito, Nunzia, Di Filippo, Isabella, Pinchera, Biagio, Foggia, Maria, Zappulo, Emanuela, Giaccone, Agnese, Schiano Moriello, Nicola, Viceconte, Giulio, Scotto, Riccardo, Bifulco, Giuseppe, Gentile, Ivan, Buonomo, Antonio Riccardo, Saccone, Gabriele, Esposito, Nunzia, Di Filippo, Isabella, Pinchera, Biagio, Foggia, Maria, Zappulo, Emanuela, Giaccone, Agnese, Schiano Moriello, Nicola, Viceconte, Giulio, Scotto, Riccardo, Bifulco, Giuseppe, and Gentile, Ivan

Abstract

Objective: To evaluate safety and efficacy of casirivimab/imdevimab therapy in pregnant women with severe COVID-19 requiring oxygen therapy. Methods: This was a prospective case series study aimed to evaluate safety and efficacy of casirivimab/imdevimab therapy in unvaccinated pregnant women with severe COVID-19. Inclusion criteria were: SARS CoV-2 infection documented with PCR, pregnancy, severe COVID-19 requiring oxygen therapy, duration of symptoms of 10 days or less, able to provide informed consent. Vaccinated women, and those with mild-to-moderate disease were excluded from the study. Included patients received casirivimab and imdevimab as single intravenous dose of 4000/4000 mg. Women were also treated with low molecular weight heparin, steroids and antibiotics, if necessary. The primary outcome was maternal death. Secondary outcomes were: rate of adverse events during infusion or within 72 hours, and rate of abortion. Results: Thirteen hospitalized unvaccinated pregnant women with severe COVID-19 requiring oxygen and treated with casirivimab/imdevimab were included in the study. We observed no maternal death, and no patients required intubation or admission to intensive care unit. No abortion or fetal loss were recorded. Nine pregnancies were still ongoing, and there were three cesarean deliveries and one vaginal delivery. Two were preterm deliveries (at 31 and 34 weeks), and two were term deliveries. Conclusion: Casirivimab/imdevimab therapy may be considered as therapy in unvaccinated pregnant women with severe COVID-19.

Published
2022

41. COVID-19 Post-Exposure Evaluation (COPE) Study: Assessing the Role of Socio-Economic Factors in Household SARS-CoV-2 Transmission within Campania Region (Southern Italy)

Author

Gentile, Ivan, Iorio, Martina, Zappulo, Emanuela, Scotto, Riccardo, Maraolo, Alberto Enrico, Buonomo, Antonio Riccardo, Pinchera, Biagio, Muto, Giuseppina, Iervolino, Carmela, Villari, Riccardo, Schiano Moriello, Nicola, Scirocco, Maria Michela, Triassi, Maria, Paternoster, Mariano, Russo, Vincenzo, Viceconte, Giulio, Federico Ii Covid-Team, null, Gentile, Ivan, Iorio, Martina, Zappulo, Emanuela, Scotto, Riccardo, Maraolo, Alberto Enrico, Buonomo, Antonio Riccardo, Pinchera, Biagio, Muto, Giuseppina, Iervolino, Carmela, Villari, Riccardo, Schiano Moriello, Nicola, Scirocco, Maria Michela, Triassi, Maria, Paternoster, Mariano, Russo, Vincenzo, Viceconte, Giulio, and Federico Ii Covid-Team, Null

Subjects
COVID-19, SARS-CoV-2, household, poverty, regional studies, Campania (Italy), Economic Factor, Health, Toxicology and Mutagenesis, Public Health, Environmental and Occupational Health, Italy, Retrospective Studie, Humans, regional studie, Economic Factors, Human, Retrospective Studies
Abstract

Campania is the sixth poorest region of Italy, and it is the region with the highest income inequality. The secondary attack rates of SARS-CoV-2 among households are found to be substantially heterogeneous among published studies and are influenced by socio-economic factors. We conducted a retrospective study to describe the role of socio-economic factors in the household transmission of SARS-CoV-2 among patients living in Campania Region and referring to “Federico II” Hospital. We interviewed 413 subjects followed-up for COVID-19 between the 8 March 2020 and the 24 May 2021 with the aim to collect demographic, clinical, economic, and social data regarding their household and the index cases. The variables associated with SARS-CoV-2 attack rate higher than 50% among households were higher age (p = 0.023) and higher Charlson Comorbidity Index of the index case (p = 0.023) and, for household characteristics, higher number of families per house (p = 0.02), location of the houses in Naples’ suburbs (Chi2 = 5.3, p = 0.02) and in Caserta City area (Chi2 = 4, p = 0.04), and renting the house compared to owning it (Chi2 = 5.83, p = 0.01). This study confirms the finding described by other authors that household transmission of SARS-CoV-2 is correlated with the income inequality of the analyzed geographical area as well as with the indicators of health and economic wealth of the families, and this correlation also applies to the Campania Region.

Published
2022

42. Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019.

Author

Buonomo, Antonio Riccardo, Filippo, Isabella Di, Esposito, Nunzia, Saccone, Gabriele, Nobile, Mariano, Viceconte, Giulio, Villari, Riccardo, Carlo, Costantino Di, Bifulco, Giuseppe, and Gentile, Ivan

Subjects
*COVID-19, *INTRAVENOUS therapy, *POST-acute COVID-19 syndrome, *MONOCLONAL antibodies, *ANTIVIRAL agents, *PREGNANT women, *SEVERITY of illness index, *TREATMENT effectiveness, *VACCINATION status, *OUTPATIENT services in hospitals, *DISEASE risk factors, *PREGNANCY
Abstract

Objective The aim of this study was to report the use casirivimab/imdevimab therapy in pregnant women with moderate coronavirus disease 2019 (COVID-19). Study Design We report 12 cases of unvaccinated pregnant patients with mild-to-moderate COVID-19 treated with casirivimab/imdevimab. Results Twelve unvaccinated pregnant patients with mild-to-moderate COVID-19 received casirivimab/imdevimab at the dose of 1200/1200 mg by intravenous infusion over 60 minutes. All women were managed outpatient. None experienced severe adverse drug reaction and none progressed to severe disease. Conclusion Casirivimab/imdevimab should be considered for outpatient treatment of unvaccinated pregnant women with mild-to-moderate COVID-19 to decrease the risk of severe disease. Key Points Casirivimab/imdevimab is not well studied in pregnant women. Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 decreases the risk of severe disease. Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 is well tolerated. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Risk Factors for Pneumocystis jirovecii Pneumonia in Non-HIV Patients Hospitalized for COVID-19: A Case-Control Study.

Author

Viceconte, Giulio, Buonomo, Antonio Riccardo, D'Agostino, Alessia, Foggia, Maria, Di Fusco, Antonio, Pinchera, Biagio, Scotto, Riccardo, Iacovazzo, Carmine, Fanasca, Luca, Messina, Gaetana, Cacciatore, Francesco, Salvatore, Paola, and Gentile, Ivan

Subjects
*PNEUMOCYSTIS pneumonia, *COVID-19, *SARS-CoV-2, *CASE-control method, *HIV infections, *HEMATOLOGIC malignancies
Abstract

Background: Very few cases of Pneumocystis jirovecii pneumonia (PJP) have been reported in COVID-19 so far, and mostly in patients with concomitant HIV infection or in solid-organ transplant recipients. Despite COVID-19 being associated with lymphopenia and the use of steroids, there are no studies specifically aimed at investigating the risk factors for PJP in COVID-19. Methods: A retrospective case-control study was performed. We matched PJP cases with controls with a 1:2 ratio, based on age ± 10 years, solid-organ transplantation (SOT), hematological malignancies, and in the setting of PJP development (ICU vs. non-ICU). A direct immunofluorescence assay on bronchoalveolar lavage fluid was used to diagnose PJP. Results: We enrolled 54 patients. Among 18 cases of PJP, 16 were diagnosed as "proven". Seven of the eighteen cases were immunocompromised, while the other patients had no previous immunological impairment. Patients with PJP had significantly lower median lymphocyte values (p = 0.033), longer COVID-19 duration (p = 0.014), a higher dose of steroid received (p = 0.026), higher CRP values (p = 0.005), and a lower SARS-CoV-2 vaccination rate than the controls (p = 0.029). Cumulative steroid dose is the independent risk factor for PJP development (OR = 1.004, 95%CI = 1–1.008, p = 0.042). Conclusions: PJP develops in COVID-19 patients regardless of immunosuppressive conditions and the severity of disease, and it is correlated to the corticosteroid dose received. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis

Author

Zappulo, Emanuela, primary, Buonomo, Antonio Riccardo, additional, Moccia, Marcello, additional, Pinchera, Biagio, additional, Villari, Riccardo, additional, Petracca, Maria, additional, Lanzillo, Roberta, additional, Scotto, Riccardo, additional, Carotenuto, Antonio, additional, Viceconte, Giulio, additional, Schiano Moriello, Nicola, additional, Bruno, Luca, additional, Gentile, Ivan, additional, and Brescia Morra, Vincenzo, additional

Published
2022
Full Text
View/download PDF

46. mTOR Inhibitor Use Is Associated With a Favorable Outcome of COVID-19 in Patients of Kidney Transplant: Results of a Retrospective Study

Author

Pinchera, Biagio, primary, Spirito, Lorenzo, additional, Buonomo, Antonio Riccardo, additional, Foggia, Maria, additional, Carrano, Rosa, additional, Salemi, Fabrizio, additional, Schettino, Elisa, additional, Papa, Fortuna, additional, La Rocca, Roberto, additional, Crocetto, Felice, additional, Napolitano, Luigi, additional, Villari, Riccardo, additional, and Gentile, Ivan, additional

Published
2022
Full Text
View/download PDF

48. Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study.

Author

Scotto, Riccardo, Buonomo, Antonio Riccardo, Iuliano, Antonio, Foggia, Maria, Sardanelli, Alessia, Villari, Riccardo, Pinchera, Biagio, Gentile, Ivan, and Federico II COVID-Team

Subjects
COVID-19, MONOCLONAL antibodies, REMDESIVIR, DRUG side effects, COVID-19 treatment
Abstract

Early treatment with antivirals against SARS-CoV-2 infection can prevent the onset of severe COVID-19 in fragile and immunocompromised patients. In this real-life, prospective, observational study, we evaluated efficacy and safety of a 3-day early treatment with remdesivir in adult and fragile patients with a diagnosis of SARS-CoV-2 infection who referred to the COVID-19 early treatment service of Infectious Diseases Unit of University of Naples Federico from 10 January 2022 to 31 March 2022. The included patients could be treated with either remdesivir alone or with remdesivir plus a monoclonal antibody with activity against SARS-CoV-2. Among the 62 included patients, we showed low rates of hospitalization (8%), increase in oxygen supplementation (3.2%), ICU admission (1.6%) and death (1.6%). The rate of disease progression was 8% and it was similar in patients treated with remdesivir alone or in combination with monoclonal antibodies (6.7% and 9.4%, respectively; p = 0.531). The rate of adverse drug reaction was low and similar in the two groups (13.3% in patients treated with remdesivir, 15.6% in patients treated with the combination; p = 0.543). Most common adverse events were headache and fever. In conclusion, in our cohort of patients at a high risk of worse COVID-19 outcomes, an early course of remdesivir showed low rates of disease progression and adverse drug reactions. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Invasive Fungal Infections in Hospitalized Patients with COVID-19: A Non-Intensive Care Single-Centre Experience during the First Pandemic Waves.

Author

Cattaneo, Letizia, Buonomo, Antonio Riccardo, Iacovazzo, Carmine, Giaccone, Agnese, Scotto, Riccardo, Viceconte, Giulio, Mercinelli, Simona, Vargas, Maria, Roscetto, Emanuela, Cacciatore, Francesco, Salvatore, Paola, Catania, Maria Rosaria, Villari, Riccardo, Cittadini, Antonio, and Gentile, Ivan

Subjects
*MYCOSES, *PNEUMOCYSTIS pneumonia, *PULMONARY aspergillosis, *HOSPITAL patients, *COMMUNICABLE diseases, *COVID-19, *MEDICAL personnel
Abstract

Invasive fungal infections (IFIs) represent a severe complication of COVID-19, yet they are under-estimated. We conducted a retrospective analysis including all the COVID-19 patients admitted to the Infectious Diseases Unit of the Federico II University Hospital of Naples until the 1 July 2021. Among 409 patients, we reported seven cases of IFIs by Candida spp., seven of Pneumocystis jirovecii pneumonia, three of invasive pulmonary aspergillosis, and one of Trichosporon asahii. None of the cases presented underlying predisposing conditions, excluding one oncohematological patient treated with rituximab. Ten cases showed lymphopenia with high rates of CD4+ < 200/µL. All cases received high-dose steroid therapy (mean duration 33 days, mean cumulative dosage 1015 mg of prednisone equivalent), and seven cases had severe COVID-19 disease (OSCI ≥ 5) prior to IFI diagnosis. The cases showed a higher overall duration of hospitalization (63 vs 24 days) and higher mortality rate (23% vs. 7%) compared with the COVID-19 patients who did not developed IFIs. Cases showed a higher prevalence of high-dose steroid therapy and lymphopenia with CD4+ < 200/µL, primarily due to SARS-CoV-2 infection and not related to underlying comorbidities. IFIs strongly impact the overall length of hospitalization and mortality. Therefore, clinicians should maintain a high degree of suspicion of IFIs, especially in severe COVID-19 patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. Diabetes and SARS-CoV-2 Infection: The Potential Role of Antidiabetic Therapy in the Evolution of COVID-19.

Author

Pinchera, Biagio, Schiano Moriello, Nicola, Buonomo, Antonio Riccardo, Di Filippo, Isabella, Tanzillo, Anastasia, Buzzo, Giorgio, Villari, Riccardo, and Gentile, Ivan

Subjects
COVID-19, COVID-19 treatment, SARS-CoV-2, HYPOGLYCEMIC agents, INFECTION
Abstract

Diabetes mellitus represents one of the most frequent comorbidities among patients with COVID-19, constituting a risk factor for a more severe prognosis than that of non-diabetic patients. However, the pathophysiological mechanism underlying this unfavorable outcome is still not completely clear. The goal of our study was to evaluate the potential role of antidiabetic therapy in the evolution of COVID-19. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results